The combination of immunostimulatory plasmid DNA encoding IL-2 and siRNA delivered by TT-LDCP NPs targeting PD-L1 in the treatment of hepatocellular carcinoma (HCC) has also been shown to significantly increase tumor infiltration and CD8+ T-cell activation (37). Here, IL2 is linked to neoplasm.